Original Research Article
Abdominal Fat, Adipose-Derived Hormones and Mild Cognitive Impairment: The J-SHIPP StudyKamogawa K.a · Kohara K.a, c · Tabara Y.b, c · Uetani E.a · Nagai T.a · Yamamoto M.a · Igase M.a · Miki T.a, c
Departments of aGeriatric Medicine and bBasic Medical Research and Education, and cProteo-Medicine Research Center, Ehime University Graduate School of Medicine, Tõon, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background/Aim: Lower body weight in later life has been shown to be associated with dementia. However, abdominal fat distribution under conditions of mild cognitive impairment (MCI) and the possible involvement of leptin and adiponectin in MCI have not been fully investigated. Methods: We analyzed 517 middle-aged-to-elderly community-dwelling persons. Abdominal subcutaneous fat and visceral fat areas were determined using computed tomography, and plasma leptin and adiponectin concentrations were measured in fasting samples. MCI was assessed using the Japanese version of the MCI screening method. Results: In men, the abdominal subcutaneous fat area was significantly lower in participants with MCI than in those with normal cognitive function [median (interquartile range): 107.4 (85.9, 133.1) cm2 vs. 136.4 (93.1, 161.4) cm2; p = 0.002]. Logistic regression analyses with confounding factors including age and abdominal subcutaneous fat area showed that a 10 mg/l increase in plasma adiponectin had a protective effect against the development of MCI in men (odds ratio: 0.46; 95% CI: 0.20–0.97; p = 0.041). In contrast, MCI was not found to be associated with abdominal fat area or adipose-derived hormones in women. Conclusion: Reduced amounts of subcutaneous fat and low levels of plasma adiponectin were found to be associated with MCI in men.
© 2010 S. Karger AG, Basel
- Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K: Central obesity and increased risk of dementia more than three decades later. Neurology 2008;71:1057–1064.
- Kanaya AM, Lindquist K, Harris TB, Launer L, Rosano C, Satterfield S, Yaffe K; Health ABC Study Group: Total and regional adiposity and cognitive change in older adults: the Health, Aging and Body Composition (ABC) study. Arch Neurol 2009;66:329–335.
- Razay G, Vreugdenhil A, Wilcock G: Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 2006;22:173–176.
- Gustafson D: Adiposity indices and dementia. Lancet Neurol 2006;5:713–720.
- Huffman DM, Barzilai N: Role of visceral adipose tissue in aging. Biochim Biophys Acta 2009;1790:1117–1123.
- Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC: Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996;44:1147–1152.
- Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B, International Psychogeriatric Association Expert Conference on Mild Cognitive Impairment: Mild cognitive impairment. Lancet 2006;367:1262–1270.
- Mitchell AJ, Shiri-Feshki M: Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252–265.
- Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK, Wong ML, Licinio J: Leptin replacement improves cognitive development. PLoS One 2008;3:e3098.
- Morrison CD: Leptin signaling in brain: a link between nutrition and cognition? Biochim Biophys Acta 2009;1792:401–408.
- Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S: Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009;302:2565–2572.
- Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–26749.
- Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
- Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226–228.
- Chen MP, Tsai JC, Chung FM, Yang SS, Hsing LL, Shin SJ, Lee YJ: Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005;25:821–826.
- Jung TW, Lee JY, Shim WS, Kang ES, Kim JS, Ahn CW, Lee HC, Cha BS: Adiponectin protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Biochem Biophys Res Commun 2006;343:564–570.
- Jeon BT, Shin HJ, Kim JB, Kim YK, Lee DH, Kim KH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS: Adiponectin protects hippocampal neurons against kainic acid-induced excitotoxicity. Brain Res Rev 2009;61:81–88.
- Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–769.
- Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T, Suzuki R, Satoh H, Tsuchida A, Moroi M, Sugi K, Noda T, Ebinuma H, Ueta Y, Kondo T, Araki E, Ezaki O, Nagai R, Tobe K, Terauchi Y, Ueki K, Minokoshi Y, Kadowaki T: Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007;6:55–68.
- Psilopanagioti A, Papadaki H, Kranioti EF, Alexandrides TK, Varakis JN: Expression of adiponectin and adiponectin receptors in human pituitary gland and brain. Neuroendocrinology 2009;89:38–47.
- Shankle WR, Romney AK, Hara J, Fortier D, Dick MB, Chen JM, Chan T, Sun X: Methods to improve the detection of mild cognitive impairment. Proc Natl Acad Sci USA 2005;102:4919–4924.
- Kido T, Tabara Y, Igase M, Ochi N, Uetani E, Nagai T, Yamamoto M, Taguchi K, Miki T, Kohara K: Postural instability is associated with brain atrophy and cognitive impairment in the elderly: the J-SHIPP study. Dement Geriatr Cogn Disord 2010;29:379–387.
- Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S: Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endocrinol Metab 2008;93:2181–2187.
- Komai H, Shibata R, Juri M, Matsushita K, Ouchi N, Murohara T: Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease. J Vasc Surg 2009;50:95–99.
- Cho A, Sugimura M, Nakano S, Yamada T: The Japanese MCI Screen for early detection of Alzheimer’s disease and related disorders. Am J Alzheimers Dis Other Demen 2008;23:162–166.
- Kim KW, Lee DY, Jhoo JH, Youn JC, Suh YJ, Jun YH, Seo EH, Woo JI: Diagnostic accuracy of Mini-Mental Status Examination and Revised Hasegawa Dementia Scale for Alzheimer’s disease. Dement Geriatr Cogn Disord 2005;19:324–330.
- Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O’Meara ES, Longstreth WT Jr, Luchsinger JA: Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009;66:336–342.
- West NA, Haan MN: Body adiposity in late life and risk of dementia or cognitive impairment in a longitudinal community-based study. J Gerontol A Biol Sci Med Sci 2009;64:103–109.
- Han C, Jo SA, Seo JA, Kim BG, Kim NH, Jo I, Park MH, Park KW: Adiposity parameters and cognitive function in the elderly: application of ‘Jolly Fat’ hypothesis to cognition. Arch Gerontol Geriatr 2009;49:e133–e138.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.